Don’t Jump to Voquezna for Erosive GERD

January 2024

Rx vonoprazan (Voquezna) will be touted as the first acid suppressant with a new mechanism of action in over 30 years.

It’s the first potassium-competitive acid blocker (PCAB)...and is now approved for erosive esophagitis.

Think of vonoprazan as a “fancy PPI”...with some differences.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Contraceptives Prepare for Opill, the First OTC Oral Contraceptive
Obesity & Weight Loss Consider Pros and Cons of Zepbound or Wegovy for Obesity
Obesity & Weight Loss Explain That Weight Loss Meds Aren’t “Magic Bullets”
Insulin Be Ready to Help Patients Switch Insulin
Gastroenterology Don’t Jump to Voquezna for Erosive GERD
Med Safety Double Down on Efforts to Improve Methotrexate Safety
Substance Use Disorder Help Manage Meds to Treat Alcohol Use Disorder
NatMed Spotlight Give Guidance About Coenzyme Q10